Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients

Table 2 Biochemical parameters before and after treatment with angiotensin converting enzyme inhibitor

Parameter	Baseline1	6 mo1,2	P-value
No. of patients	n = 252	n = 252
Blood urea (mmol/L)	2.22 ± 0.86	2.01 ± 0.77	0.661
Serum creatinine (μmol/L)	95.47-30	99-28.28	0.068
Serum sodium (mmol/L)	139.47 ± 4.11	135.14 ± 3.88	0.512
Serum potassium (mmol/L)	4.32 ± 0.65	4.30 ± 0.52	0.141
eGFR (MDRD) mL/min per 1.73 m2	73.65 ± 24.71	68.90 ± 24.44	0.081
eGFR (EPI) mL/min per 1.73 m2	73.40 ± 22.8	70.56 ± 21.30	0.07
Fasting plasma glucose (mmol/L)	7.63 ± 0.60	6.693 ± 0.81	0.08
Post-prandial plasma glucose (mmol/L)	10.33 ± 1.62	8.52 ± 1.3	0.076
HbA1c (%)	6.52 ± 1.71	6.1 ± 1.14	0.06
Hemoglobin (g/L)	123.8 ± 23	111.2 ± 31	0.65
Systolic blood pressure (mmHg)	132.30 ± 13.67	130.12 ± 10.46	0.71
Diastolic blood pressure (mmHg)	86.10 ± 10.03	84.07 ± 8.32	0.68

¹Data are presented as mean ± SD;

²P > 0.05. HbA1c: Hemoglobin A1c; eGFR: Estimated glomerular filtration rate.